Oval Medical Technologies

Oval Medical Technologies is a drug delivery device design and development company, specialising in patient-centric autoinjectors. The company develops devices to handle a wide range of formulation requirements, with designs that include proprietary custom primary containers.

Associated Companies

SMC Ltd Cambridge Pharma

Headquarters
Oval Medical Technologies Ltd
Unit 3, Enterprise 3930
Cambridge Research Park
Beach Drive
Waterbeach
Cambridge
CB25 9PE

Phone / Contact

T: +44 1223 736 220
E: [email protected]

Connect

Oval Medical Technologies focuses on the design of novel autoinjector systems for parenteral drug delivery. Oval employs a patient-centric approach in its design work, tailoring development to the specific needs of the target patient population, as well as the requirements of the drug formulation itself. Oval designs its devices around novel cyclo-olefin polymer primary drug containers, which it uses to handle formulation requirements, such as high-viscosity, high-volume and fragile molecules.

Oval produces the ArQ range of autoinjector platforms, which includes:

ArQ – subcutaneous delivery <100 cP
ArQ-Bios – subcutaneous delivery >100 cP
ArQ-Tempo – intramuscular small volume
ArQ-Vita – intramuscular large volume.

Oval also offers drug-device combination products, including Sumalen Ovali (sumatripan succinate) and EPIQ (epinephrine).

Oval is based in Cambridge, UK, was founded in 2009 by Matthew Young and was acquired by SMC Ltd in 2016. Oval has a quality system compliant with BS EN 13485:2016, FDA 21 CFR Pt 820, Medical Device Directive 93/42/EEC and ANSI/AAMI HE75.

Articles by Oval Medical Technologies

PREFILLED SYRINGES

Asmita Khanolkar

ACCELERATING NOVEL THERAPIES TO THE CLINIC – CUSTOM SOLUTIONS

Asmita Khanolkar discusses the key offerings necessary to accelerate “speed to clinic” for custom manufacturing solutions.

SUSTAINABILITY CONSIDERATIONS FOR END-TO-END DRUG DELIVERY DEVICE SOLUTIONS

Barbara Lead outlines the sustainability efforts undertaken by SMC Group associated companies, including facilitating the transition from hospital to at-home treatment and investment in greener facilities.

Olivia Jefferies

COMPUTATIONAL MODELLING OF INJECTION-RELATED TISSUE RESPONSES IN DRUG DELIVERY

Olivia Jefferies, Elizabeth Margerison and Asmita Khanolkar introduce Oval’s work on using ultrasound scanning and finite element analysis to construct a model of how tissue compresses under use of an autoinjector across patient demographics, and how this may provide insights into improved autoinjector design for more accurate injection depths, improving patient outcomes.

Asmita Khanolkar

A NEW MINDSET FOR COMBINATION PRODUCT DEVELOPMENT

Asmita Khanolkar outlines the latest trends in combination product development to overcome some of the current challenges of high dose/viscosity/volume delivery.

Marcus Agunloye

PATIENT-CENTRICITY: THE IMPORTANCE OF HUMAN FACTORS IN THE PANDEMIC ERA

Marcus Agunloye and Asmita Khanolkar, Senior Director discuss how patient-centricity is at the heart of drug delivery device design and innovation, and how the global pandemic has highlighted the importance of patient-centric development in this field.

PREFILLED SYRINGES

VERIFYING THE CONTAINER CLOSURE INTEGRITY OF CUSTOM PRIMARY PACKAGING

Alex Vasiev, Connor Everett and Steven Hay explore the challenges of verifying the container closure integrity of custom primary packaging.

INDUSTRIALISATION

INTEGRATING DESIGN AND INDUSTRIALISATION TO OPTIMISE COST, QUALITY & TIME

Pete Evans and Meredith Canty explore how integrating design and industrialisation teams can optimise the cost, quality and time of developing a novel drug delivery system.

Marta Vilaplana

FUNCTION-BASED PRIMARY PACKAGING DESIGN FOR INJECTING VISCOUS NON-NEWTONIAN FORMULATIONS

Marta Vilaplana; Alex Vasiev and Susie White explore the challenges of delivering high-viscosity, non-Newtonian fluids emphasising the importance of robust tools to characterise specific device and formulation parameters in light of increasing regulatory scrutiny.

PREFILLED SYRINGES

Jonathan Bradshaw

COMBINING HUMAN NEEDS WITH HIGH VISCOSITY FORMULATIONS

Jonathan Bradshaw and Susie White discuss the requirements of designing an autoinjector capable of handling the high pressures necessary for the delivery of highly viscous drug formulations with minimal impact on the patient.

PREFILLED SYRINGES

Jonathan Lawson

USING POLYMERIC PDC TECHNOLOGY TO IMPROVE AUTO-INJECTOR DESIGN

The limitations of using glass-based auto-injectors, such as contamination, and the need for delivering complex, viscous preparations, have led to a new approach that uses polymeric PDC technology instead. Jonathan Lawson, Jonathan Bradshaw and Susie White look at what polymeric PDCs can offer in making auto-injectors truly patient-centric.

Top